This paper reviews the conventional and more novel approaches to managing and extending the lifecycle of pharmaceutical products. In the context of stringent marketing regulations and an increasingly competitive landscape, greater emphasis will need to be placed on when and how each phase of a product's lifecycle is managed in order to maximise return on investment. This paper describes each of the lifecycle management strategies currently practiced, when and how they might be used, and provides selected examples of implementation.
Get full access to this article
View all access options for this article.
References
1.
BruceL. (2003). Defending value and maximizing profitability of innovative pharmaceuticals over their entire life cycles. Int. J. Med. Market3, 195–197.
SahooA. (2006). Lifecycle Management Strategies. Maximizing ROI through Indication Expansion, Reformulation and RX-to-OTC Switching, Business Insights Ltd., London.
7.
BarakA.WilsonG. (2003). Pricing policies to handle patent loss or expiry. Int. J. Med. Market. 3, 245–249.
8.
LevittT. (1965). Exploit the product life cycle. Harvard Bus. Rev. 43, 81–93.
9.
BurdonM.SloperK. (2003). The art of using secondary patents to improve protection. Int. J. Med. Market. 3, 226–238.
10.
TuttleE.PareceA.HectorA. (2004). Your patent is about to expire: What now?Pharma. Exec. 24, 88–98.
Lifecycle management in the pharmaceutical industry: The unexploited potential, 〈(www.capgemini.com/lifesciences〉), Capgemini, accessed 3rd February, 2008.
13.
HansenN. (2007). Introduction of lifecycle management and selecting the best brand protection strategy. Proceedings of the International Workshop on Optimizing Brand Strategies in the Face of Generic Competition, Brussels, Belgium.
14.
ChandonP. (2004). Innovative marketing strategies after patent expiry: The case of GSK's antibiotic Clamoxyl in France. Int. J. Med. Market. 4, 65–73.
15.
DohertyG.EnnewC. T. (1995). The marketing of pharmaceuticals: Standardization or customization?J. Market. Pract. 3, 39–50.
16.
ViswanathanN. K.DicksonP. R. (2007). The fundamentals of standardizing global marketing strategy. Int. Market. Rev. 24, 46–63.
17.
SinclairA. (2007). Reformulation of second generation product strategy. Proceedings of the International Workshop on Optimizing Brand Strategies in the Face of Generic Competition, Brussels, Belgium.
18.
PhilippT.SmithT. R.GlazerR.WernsingM.YenJ.JinJ.SchneiderH.PospiechR. (2007). Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther. 29, 563–580.
HatchO.WaxmanH. (1984). Drug price competition and patent term restoration act (Public Law 98-417). United States Federal Law.
21.
LucasJ.BurgessP. (2004). When form equals substance: The value of form screening in product life-cycle management. PharmaVoice February, 54–57.
22.
CohenJ. P.PaquetteC.CairnsC. P. (2005). Switching prescription drugs to over-the-counter, BMJ330, 39–41.
23.
ChertkowJ. (2007). Overview of the generics market and authorized generic strategy. Proceedings of the International Workshop on Optimizing Brand Strategies in the Face of Generic Competition, Brussels, Belgium.
